Transcriptional regulation of the human soluble epoxide hydrolase gene EPHX2

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1779, Issue 1, 2008, Pages 17-27

  Tanaka, Hiromasa ^a   Kamita, Shizuo G ^a   Wolf, Nicola M ^a   Harris, Todd R ^a   Wu, Zhaoju ^a   Morisseau, Christophe ^a   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

EPHX2; Epoxide hydrolase; Promoter; Transcription

Indexed keywords

5' FLANKING REGION; BASE SEQUENCE; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; CYTOGENETICS; DNA PRIMERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EPOXIDE HYDROLASES; GC RICH SEQUENCE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENES, REPORTER; HUMANS; MOLECULAR SEQUENCE DATA; PLASMIDS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION, GENETIC;

EID: 39449131197     PISSN: 18749399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2007.11.005     Document Type: Article

References (67)

1. Larsson C., White I., Johansson C., Stark A., and Meijer J. Localization of the human soluble epoxide hydrolase gene (EPHX2) to chromosomal region 8p21-p12. Hum. Genet. 95 (1995) 356-358
2. Morisseau C., and Hammock B.D. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 311-333
3. Newman J.W., Morisseau C., and Hammock B.D. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog. Lipid Res. 44 (2005) 1-51
4. Carroll M.A., Schwartzman M., Capdevila J., Falck J.R., and McGiff J.C. Vasoactivity of arachidonic acid epoxides. Eur. J. Pharmacol. 138 (1987) 281-283
5. Medhora M., and Harder D. Functional role of epoxyeicosatrienoic acids and their production in astrocytes: approaches for gene transfer and therapy (review). Int. J. Mol. Med. 2 (1998) 661-669
6. Roman R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82 (2002) 131-185
7. Spiecker M., and Liao J.K. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch. Biochem. Biophys. 433 (2005) 413-420
8. Capdevila J.H., Nakagawa K., and Holla V. The CYP P450 arachidonate monooxygenases: enzymatic relays for the control of kidney function and blood pressure. Adv. Exp. Med. Biol. 525 (2003) 39-46
9. Sun J., Sui X., Bradbury J.A., Zeldin D.C., Conte M.S., and Liao J.K. Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ. Res. 90 (2002) 1020-1027
10. Imig J.D., Zhao X., Capdevila J.H., Morisseau C., and Hammock B.D. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39 (2002) 690-694
11. Imig J.D., Zhao X., Zaharis C.Z., Olearczyk J.J., Pollock D.M., Newman J.W., Kim I.H., Watanabe T., and Hammock B.D. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46 (2005) 975-981
12. Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., Zeldin D.C., and Liao J.K. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285 (1999) 1276-1279
13. Yu Z., Xu F., Huse L.M., Morisseau C., Draper A.J., Newman J.W., Parker C., Graham L., Engler M.M., Hammock B.D., Zeldin D.C., and Kroetz D.L. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ. Res. 87 (2000) 992-998
14. Schmelzer K.R., Kubala L., Newman J.W., Kim I.H., Eiserich J.P., and Hammock B.D. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 9772-9777
15. Zhao X., Yamamoto T., Newman J.W., Kim I.H., Watanabe T., Hammock B.D., Stewart J., Pollock J.S., Pollock D.M., and Imig J.D. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J. Am. Soc. Nephrol. 15 (2004) 1244-1253
16. Inceoglu B., Jinks S.L., Schmelzer K.R., Waite T., Kim I.H., and Hammock B.D. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci. 79 (2006) 2311-2319
17. Hammock B.D., Storms D.H., and Grant D.F. Epoxide Hydrolases. In: Guengerich F.P. (Ed). Comprehensive Toxicology (1997), Pergamon, Oxford 283-305
18. Newman J.W., Morisseau C., Harris T.R., and Hammock B.D. The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 1558-1563
19. Tran K.L., Aronov P.A., Tanaka H., Newman J.W., Hammock B.D., and Morisseau C. Lipid sulfates and sulfonates are allosteric competitive inhibitors of the N-terminal phosphatase activity of the mammalian soluble epoxide hydrolase. Biochemistry 44 (2005) 12179-12187
20. Wang P., Meijer J., and Guengerich F.P. Purification of human liver cytosolic epoxide hydrolase and comparison to the microsomal enzyme. Biochemistry 21 (1982) 5769-5776
21. Yu Z., Davis B.B., Morisseau C., Hammock B.D., Olson J.L., Kroetz D.L., and Weiss R.H. Vascular localization of soluble epoxide hydrolase in the human kidney. Am. J. Physiol. Renal Physiol. 286 (2004) F720-F726
22. Waechter F., Bentley P., Bieri F., Muakkassah-Kelly S., Staubli W., and Villermain M. Organ distribution of epoxide hydrolases in cytosolic and microsomal fractions of normal and nafenopin-treated male DBA/2 mice. Biochem. Pharmacol. 37 (1988) 3897-3903
23. Oesch F., Schladt L., Hartmann R., Timms C., and Worner W. Rat cytosolic epoxide hydrolase. Adv. Exp. Med. Biol. 197 (1986) 195-201
24. Petruzzelli S., Franchi M., Gronchi L., Janni A., Oesch F., Pacifici G.M., and Giuntini C. Cigarette smoke inhibits cytosolic but not microsomal epoxide hydrolase of human lung. Hum. Exp. Toxicol. 11 (1992) 99-103
25. Pacifici G.M., Temellini A., Giuliani L., Rane A., Thomas H., and Oesch F. Cytosolic epoxide hydrolase in humans: development and tissue distribution. Arch. Toxicol. 62 (1988) 254-257
26. Wixtrom R.N., Silva M.H., and Hammock B.D. Cytosolic epoxide hydrolase in human placenta. Placenta 9 (1988) 559-563
27. Enayetallah A.E., French R.A., Thibodeau M.S., and Grant D.F. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J. Histochem. Cytochem. 52 (2004) 447-454
28. Sevanian A., Stein R.A., and Mead J.F. Lipid epoxide hydrolase in rat lung preparations. Biochim. Biophys. Acta 614 (1980) 489-500
29. Zheng J., Plopper C.G., Lakritz J., Storms D.H., and Hammock B.D. Leukotoxin-diol: a putative toxic mediator involved in acute respiratory distress syndrome. Am. J. Respir. Cell Mol. Biol. 25 (2001) 434-438
30. Pham M.A., Magdalou J., Totis M., Fournel-Gigleux S., Siest G., and Hammock B.D. Characterization of distinct forms of cytochromes P-450, epoxide metabolizing enzymes and UDP-glucuronosyltransferases in rat skin. Biochem. Pharmacol. 38 (1989) 2187-2194
31. Pinot F., Grant D.F., Spearow J.L., Parker A.G., and Hammock B.D. Differential regulation of soluble epoxide hydrolase by clofibrate and sexual hormones in the liver and kidneys of mice. Biochem. Pharmacol. 50 (1995) 501-508
32. Hennebold J.D., Mah K., Perez W., Vance J.E., Stouffer R.L., Morisseau C., Hammock B.D., and Adashi E.Y. Identification and characterization of an ovary-selective isoform of epoxide hydrolase. Biol. Reprod. 72 (2005) 968-975
33. Hammock B.D., and Ota K. Differential induction of cytosolic epoxide hydrolase, microsomal epoxide hydrolase, and glutathione S-transferase activities. Toxicol. Appl. Pharmacol. 71 (1983) 254-265
34. Ai D., Fu Y., Guo D., Tanaka H., Wang N., Tang C., Hammock B.D., Shyy J.Y., and Zhu Y. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 9018-9023
35. Park W.Y., Hwang C.I., Im C.N., Kang M.J., Woo J.H., Kim J.H., Kim Y.S., Kim H., Kim K.A., Yu H.J., Lee S.J., Lee Y.S., and Seo J.S. Identification of radiation-specific responses from gene expression profile. Oncogene 21 (2002) 8521-8528
36. Stone K.R., Mickey D.D., Wunderli H., Mickey G.H., and Paulson D.F. Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer 21 (1978) 274-281
37. Leibovitz A., Stinson J.C., McCombs III W.B., McCoy C.E., Mazur K.C., and Mabry N.D. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 36 (1976) 4562-4569
38. Fogh J., Wright W.C., and Loveless J.D. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58 (1977) 209-214
39. Pear W.S., Nolan G.P., Scott M.L., and Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 8392-8396
40. Goldstein M.N., Slotnick I.J., and Journey L.J. In vitro studies with HeLa cell line sensitive and resistant to actinomycin D. Ann. N. Y. Acad. Sci. 89 (1960) 474-483
41. Nakabayashi H., Taketa K., Miyano K., Yamane T., and Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 42 (1982) 3858-3863
42. Borden E.C., Hogan T.F., and Voelkel J.G. Comparative antiproliferative activity in vitro of natural interferons a and b for diploid and transformed human cells. Cancer Res. 42 (1982) 4948-4953
43. Naito S., von Eschenbach A.C., Giavazzi R., and Fidler I.J. Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res. 46 (1986) 4109-4115
44. Aden D.P., Fogel A., Plotkin S., Damjanov I., and Knowles B.B. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 282 (1979) 615-616
45. Gross-Bellard M., Oudet P., and Chambon P. Isolation of high-molecular-weight DNA from mammalian cells. Eur. J. Biochem. 36 (1973) 32-38
46. Borhan B., Mebrahtu T., Nazarian S., Kurth M.J., and Hammock B.D. Improved radiolabeled substrates for soluble epoxide hydrolase. Anal. Biochem. 231 (1995) 188-200
47. Smale S.T., Schmidt M.C., Berk A.J., and Baltimore D. Transcriptional Activation by Sp1 as Directed Through TATA or Initiator: Specific Requirement for Mammalian Transcription Factor IID 87 (1990) 4509-4513
48. Smale S.T. Transcription initiation from TATA-less promoters within eukaryotic protein-coding genes. Biochim. Biophys. Acta 1351 (1997) 73-88
49. Dynan W.S., and Tjian R. The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV40 early promoter. Cell 35 (1983) 79-87
50. Kadonaga J.T., Carner K.R., Masiarz F.R., and Tjian R. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell 51 (1987) 1079-1090
51. Kadonaga J.T., and Tjian R. Affinity purification of sequence-specific DNA binding proteins. Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 5889-5893
52. Briggs M.R., Kadonaga J.T., Bell S.P., and Tjian R. Purification and biochemical characterization of the promoter-specific transcription factor, Sp1. Science 234 (1986) 47-52
53. Davis B.B., Thompson D.A., Howard L.L., Morisseau C., Hammock B.D., and Weiss R.H. Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 2222-2227
54. Xu D., Li N., He Y., Timofeyev V., Lu L., Tsai H.J., Kim I.H., Tuteja D., Mateo R.K., Singapuri A., Davis B.B., Low R., Hammock B.D., and Chiamvimonvat N. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 18733-18738
55. M.P. Hutchens, T. Nakano, J. Dunlap, R.J. Traystman, P.D. Hurn, N.J. Alkayed, Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation, Resuscitation (in press) (available online 28 August 2007).
56. Michaelis U.R., Fisslthaler B., Medhora M., Harder D., Fleming I., and Busse R. Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). FASEB J. 17 (2003) 770-772
57. Enayetallah A.E., French R.A., and Grant D.F. Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms. J. Mol. Histol. 37 (2006) 133-141
58. Hammock B.D., Gill S.J., Mumby S.M., and Ota K. Comparison of epoxide hydrases in the soluble and microsomal fractions of mammalian liver. In: Bhatnagar R.S. (Ed). Molecular Basis of Environmental Toxicity (1980), Ann Arbor Science, Ann Arbor 229-272
59. Roche P.J., Hoare S.A., and Parker M.G. A consensus DNA-binding site for the androgen receptor. Mol. Endocrinol. 6 (1992) 2229-2235
60. Juge-Aubry C., Pernin A., Favez T., Burger A.G., Wahli W., Meier C.A., and Desvergne B. DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5′-flanking region. J. Biol. Chem. 272 (1997) 25252-25259
61. Lewis J.D., Meehan R.R., Henzel W.J., Maurer-Fogy I., Jeppesen P., Klein F., and Bird A. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 69 (1992) 905-914
62. Li E., Bestor T.H., and Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69 (1992) 915-926
63. Brandeis M., Frank D., Keshet I., Siegfried Z., Mendelsohn M., Nemes A., Temper V., Razin A., and Cedar H. Sp1 elements protect a CpG island from de novo methylation. Nature 371 (1994) 435-438
64. Kaczynski J., Cook T., and Urrutia R. Sp1- and Kruppel-like transcription factors. Genome Biol. 4 (2003) 206
65. Pichare M.M., and Gill S.S. The regulation of cytosolic epoxide hydrolase in mice. Biochem. Biophys. Res. Commun. 133 (1985) 233-238
66. VanRollins M., Kaduce T.L., Knapp H.R., and Spector A.A. 14, 15-Epoxyeicosatrienoic acid metabolism in endothelial cells. J. Lipid Res. 34 (1993) 1931-1942
67. Enayetallah A.E., French R.A., Barber M., and Grant D.F. Cell-specific subcellular localization of soluble epoxide hydrolase in human tissues. J. Histochem. Cytochem. 54 (2006) 329-335